Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing treatment for malignancy by at the University of Chicago with any agent with recognized, specific inhibition of VEGF, VEGF-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. These agents include but are not limited to: bevacizumab (Avastin™), sorafenib (Nexavar™), sunitinib (Sutent™), axitinib (AG-013736), and AZD 2171.~* Treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmHg.~* Stable management of other toxicities from the cancer treatments~* Expected to continue current cancer treatments for at least 4 weeks~* 18 years and older~* Ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.~Exclusion Criteria:~* Concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.~* Current uncontrolled toxicities due to the cancer treatments.~* Patients having known contraindications to hydralazine or minoxidil therapy.~* Any readings of systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg in the four (4) weeks prior to screening.~* Use of either minoxidil or hydralazine in the six (6) months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Minoxidil
- 2 (Type: ACTIVE_COMPARATOR): Hydralazine

Based on this trial design, predict the completion outcome and termination type (if applicable).